Users may navigate the dashboard using the following tips:

• Bookmarks at the top right corner of the dashboard can be used to navigate to various pages of the dashboard.
• Multiple selections can be made within the "disease, carbapenemase, and facility type" filters by holding CTRL while clicking on the desired values.
• Visuals with specimen collection date can be drilled down from year to quarter or month by clicking on the icons with downward arrows.
• Hovering over values in visuals can produce tooltips with further information.

Footnotes

1. Targeted MDRO = Multidrug-resistant organisms (MDRO) that are of epidemiologic and/or clinical importance, allocating more prevention and containment response and activities to prevent further transmission. Organisms included in this category may include but are not limited to Candida auris, CP-AB, and CP-PA.
2. Carbapenemase = A genetically-encoded antibiotic resistance enzyme that allow bacteria to become resistant to carbapenems (e.g. meropenem) and other beta-lactam antibiotics. Carbapenemases can be identified via genotypic testing, which identifies a known carbapenemase (e.g. KPC, NDM, OXA-48, VIM, IMP), or phenotypic testing, which results in no gene identification.
3. CPO = Carbapenemase-producing organism. CPO are bacteria that produce a carbapenemase enzyme. CPO can include Acinetobacter baumannii, Pseudomonas aeruginosa, and bacteria in the Enterobacterales order.
4. CPAB = Carbapenemase-producing Acinetobacter baumannii
5. CP-CRE = Carbapenemase-producing carbapenem-resistant Enterobacterales, including but not limited to Escherichia coli (E. coli), Klebsiella pneumoniae, and Enterobacter species.
6. CPPA = Carbapenemase-producing Pseudomonas aeruginosa
7. Candida auris (C. auris) = A fungus that is of particular health concern because it: can cause severe, antibiotic-resistant infections; is difficult to identify using traditional yeast identification methods; can survive on healthcare setting surfaces for long periods; and can spread easily to patients in healthcare settings.
8. Clinical case = A patient who has a positive specimen that was collected for the purpose of diagnosing or treating disease in the normal course of care. This includes specimens from sites reflecting invasive infection (e.g., blood, cerebrospinal fluid) and specimens from non-invasive sites such as wounds, urine, and the respiratory tract. Note, presence of C. auris from non-invasive sites may represent colonization and not true infection.
9. Colonized case = A patient who has asymptomatic colonization, but no evidence of infection, with an organism. Colonization testing is conducted using bilateral axilla/groin swabs for C. auris and rectal swabs for CPO.
10. Surveillance-to-clinical case = A patient who was first identified as a colonized case, then later identified as a clinical case through one or more positive clinical specimen(s).
11. GACH = General Acute Care Hospital
12. LTACH = Long-Term Acute Care Hospital
13. SNF = Skilled Nursing Facility
14. OUT = Outpatient Facility
15. OOC = Out of County Healthcare Facilities. Cases from these healthcare facilities are included in the data because they are residents of LAC.

Data Sources:

The MDRO data were reported by laboratories and healthcare providers in response to state or local reporting requirements. Not all reported cases are investigated; some MDRO are not targeted for response due to their epidemiology and clinical outcomes.

Patient demographic data may be suppressed if aggregated values are less than 12 and are represented by an asterisk (*). Unknown values are not displayed in visuals.

Please see our LAC NHSN HAI Dashboard for CRE and other HAI data.